Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8835681 | 0.86 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL10572049 | 0.84 | DGAT1 (0.34) | DGAT1ALDH1A1 | |
| SCHEMBL77789 | 0.81 | DGAT1 (0.40) | DGAT1USP2SMN1; SMN2ALDH1A1ELANE | |
| SCHEMBL796349 | 0.81 | DGAT1 (0.40) | DGAT1USP2SMN1; SMN2ALDH1A1ELANE | |
| SCHEMBL77788 | 0.81 | DGAT1 (0.40) | DGAT1USP2SMN1; SMN2ALDH1A1ELANE | |
| SCHEMBL10883537 | 0.80 | — | — | |
| SCHEMBL4982584 | 0.80 | DGAT1 (0.32) | DGAT1ALDH1A1 | |
| SCHEMBL12761175 | 0.79 | — | — | |
| SCHEMBL396036 | 0.79 | — | — | |
| SCHEMBL10423459 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112759595-B | Method for synthesizing chiral acyclic nucleoside by asymmetric allylation reaction | 河南师范大学 | 2023-01-20 | — | — | CN | claimed |
| CN-112759595-A | Method for synthesizing chiral acyclic nucleoside by asymmetric allylation reaction | 河南师范大学 | 2021-05-07 | — | — | CN | claimed |
| EP-0871619-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | claimed |
| WO-1997024343-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | claimed |
| CN-120118068-A | Chemical process for preparing phenylpiperidinyl indole derivatives | 诺华股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-112513025-B | Chemical process for preparing phenylpiperidinyl indole derivatives | 诺华股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024049976-A1 | N-METHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE COMPOUNDS | ABBVIE INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116438179-A | Pyrazole derivatives as RET kinase inhibitors | 伊莱利利公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | disclosed |
| US-11578053-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | NOVARTIS AG (CH) | 2023-02-14 | — | — | US | disclosed |
| CN-112759595-B | Method for synthesizing chiral acyclic nucleoside by asymmetric allylation reaction | 河南师范大学 | 2023-01-20 | — | — | CN | disclosed |
| US-5166198-A | Herpes virus infections | BEECHAM P.L.C. (GB) | 1992-11-24 | — | — | US | disclosed |
| US-5108994-A | Synergistic with interferon; herpes virus | BEECHAM GROUP P.L.C. (GB) | 1992-04-28 | — | — | US | disclosed |
| EP-0477789-A1 | 1,3-Benzoxazine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-04-01 | — | — | EP | disclosed |
| WO-1992001698-A1 | ANTIVIRAL PHOSPHONO-ALKEN DERIVATIVES OF PURINES | BEECHAM GROUP PLC (GB) | 1992-02-06 | — | — | WO | disclosed |
| EP-0404296-A1 | Phosphono derivatives of purine with antiviral activity | Beecham Group p.l.c. (GB) | 1990-12-27 | — | — | EP | disclosed |
| EP-0399743-A1 | Phosphonomethylthio-alkoseypureine derivatives, intermediate products for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-11-28 | — | — | EP | disclosed |
| EP-0233838-A2 | Neurite-promoting factor and process for the manufacture thereof | INCYTE PHARMACEUTICALS, INC. (US) | 1987-08-26 | — | — | EP | disclosed |
| US-4205169-A | N-[4-Azido-5-(2-ethoxyethyl)-6-phenyl-2-pyrimidinyl]acetamide and congeners | G. D. SEARLE & CO. (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578053-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | IDO1, CYP3A7, PAH | DGAT1 4667/4885USP2 4259/4885SMN1; SMN2 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.